NO880141L - IMPROVED FIBRINOLYTIC MIXING. - Google Patents

IMPROVED FIBRINOLYTIC MIXING.

Info

Publication number
NO880141L
NO880141L NO880141A NO880141A NO880141L NO 880141 L NO880141 L NO 880141L NO 880141 A NO880141 A NO 880141A NO 880141 A NO880141 A NO 880141A NO 880141 L NO880141 L NO 880141L
Authority
NO
Norway
Prior art keywords
fibrinolytic
approx
enzyme
mixing
weight
Prior art date
Application number
NO880141A
Other languages
Norwegian (no)
Other versions
NO880141D0 (en
Inventor
Robert L Hunter
Alexander Duncan
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/045,459 external-priority patent/US4801452A/en
Priority claimed from PCT/US1987/001067 external-priority patent/WO1987006836A1/en
Application filed by Univ Emory filed Critical Univ Emory
Publication of NO880141D0 publication Critical patent/NO880141D0/en
Publication of NO880141L publication Critical patent/NO880141L/en
Priority to NO922262A priority Critical patent/NO922262D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids

Abstract

En blanding son effektivt oppleser blodklumper og reetable-. rer og oppretter blodstrømmen gjennom kransarterier eller andre blodkar hvor det har vært en trombose. Den fibrinolytiske blandingen ifølge foreliggende oppfinnelse består av et enzym, f.eks. streptokinase, urokinase, vevsplasminogenaktivator eller et annet fibrinolytisk enzym, og en overflateaktiv kopolymer. Sistnevnte kan vsre et etylenoksyd-propylenoksyd-kondensasjons-produkt med følgende generelle formel:. hvor a er et tall, slik at den hydrofobe delen representert ved (CH0), har en molekylvekt fra ca. 950 til 4000, fortrinnsvis fra 175til 4000, og b er et slikt tall at den hydrofile delen representert ved (CH0), utgjør fra ca. 50 til ca. 90 vekt% av forbindelsen.A mixture that effectively dissolves blood clots and reetables. and establishes blood flow through the coronary arteries or other blood vessels where there has been a thrombosis. The fibrinolytic composition of the present invention consists of an enzyme, e.g. streptokinase, urokinase, tissue plasminogen activator or other fibrinolytic enzyme, and a surfactant copolymer. The latter may be an ethylene oxide-propylene oxide condensation product having the following general formula:. where a is a number such that the hydrophobic moiety represented by (CHO) has a molecular weight of from about 950 to 4000, preferably from 175 to 4000, and b is such a number that the hydrophilic part represented by (CH0), constitutes from approx. 50 to approx. 90% by weight of the compound.

NO880141A 1986-05-15 1988-01-14 IMPROVED FIBRINOLYTIC MIXING. NO880141L (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO922262A NO922262D0 (en) 1986-05-15 1992-06-09 IMPROVED FIBRINOLYTIC MIXING

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86358286A 1986-05-15 1986-05-15
US4388887A 1987-04-29 1987-04-29
US07/045,459 US4801452A (en) 1986-05-15 1987-05-07 Fibrinolytic composition
PCT/US1987/001067 WO1987006836A1 (en) 1986-05-15 1987-05-08 Fibrinolytic composition

Publications (2)

Publication Number Publication Date
NO880141D0 NO880141D0 (en) 1988-01-14
NO880141L true NO880141L (en) 1988-03-14

Family

ID=27488885

Family Applications (1)

Application Number Title Priority Date Filing Date
NO880141A NO880141L (en) 1986-05-15 1988-01-14 IMPROVED FIBRINOLYTIC MIXING.

Country Status (2)

Country Link
MC (1) MC1856A1 (en)
NO (1) NO880141L (en)

Also Published As

Publication number Publication date
MC1856A1 (en) 1988-12-19
NO880141D0 (en) 1988-01-14

Similar Documents

Publication Publication Date Title
EP0318201B1 (en) Inhibition of arterial thrombotic occlusion or thromboembolism
Ambrus et al. Plasmin-antiplasmin complex as a reservoir of fibrinolytic enzyme
CA1134295A (en) Enzyme derivatives for use in the treatment of venous thrombosis
ATE174510T1 (en) PREPARATION FOR THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS CONTAINING CHLORINE DIOXIDE
CA2006953A1 (en) Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids.
DE3850531T2 (en) Tissue plasminogen activator.
JPS6236502B2 (en)
Randolph et al. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli
Dosekun et al. Ancrod in systemic lupus erythematosus with thrombosis: clinical and fibrinolysis effects
DE69737500T2 (en) Purified multimerase
Zamarron et al. Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro
NO880141L (en) IMPROVED FIBRINOLYTIC MIXING.
EP0151593A1 (en) Enzyme derivatives.
EP0624642B1 (en) Novel thrombolytic agent, process for preparing same and its use for the preparation of a thrombi dissolving medicament
US4349630A (en) Heat-resistant water soluble urokinase derivative
Nieuwenhuizen et al. Factors influencing the structure of terminal plasmin degradation products of human fibrinogen and fibrin
Wentzel et al. High toxicity of pure botulinum type D toxin
Wells et al. Rheologic impairment of the microcirculation during decompression sickness
Ginsburg et al. The action of some water-soluble poly-α-amino acids on fibrinolysis
RU2416643C2 (en) Immobilised bacillus licheniformis bacteria produced subtilisin showing thrombolytic and anticoagulant properties
EP0242653B1 (en) Tpa-containing medical composition and use thereof
Lundin Acetylcholinesterase in goldfish muscles. Studies on some substrates and inhibitors
DE4442665A1 (en) Chimeric proteins with fibrinolytic and thrombin-inhibiting properties
GB2051103A (en) Heparin fractions
IE922400L (en) Composition comprising an oxygen radical scavenger and a¹surface-active copolymer